Welcome to our dedicated page for American Well SEC filings (Ticker: AMWL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Telehealth revenue models, multi-year platform investments, and value-based care contracts make American Well Corporation’s disclosures dense reading. If you have ever searched “American Well SEC filings explained simply” or wondered how board decisions affect the hybrid-care roadmap, you know that a single footnote in the 10-K can change your valuation thesis. Add insider moves and sudden 8-K announcements and the research pile grows quickly.
Our SEC Filings hub removes that friction. The moment EDGAR posts a new document—whether it is an “American Well quarterly earnings report 10-Q filing” or an “American Well 8-K material events explained”—our system flags it, then feeds it to Stock Titan’s AI engine. You receive concise overviews, key metric extractions, and contextual links, so “understanding American Well SEC documents with AI” takes minutes, not late nights. Need to monitor “American Well insider trading Form 4 transactions”? We stream “American Well Form 4 insider transactions real-time” and highlight option grants, automatic sales, and beneficial-owner changes in plain language.
Investors use this page to drill into specifics that drive telehealth economics. The “American Well annual report 10-K simplified” section outlines segment revenue for virtual primary care, platform licensing, and professional services. Each “American Well earnings report filing analysis” tracks visit volumes, payer mix, and margin trends across the care continuum. A dedicated tab surfaces “American Well proxy statement executive compensation” so you can compare stock awards to clinical-outcome targets. Practical use cases include spotting “American Well executive stock transactions Form 4” before earnings calls, mapping deferred revenue shifts across quarters, and following R&D spend tied to strategic partnerships. All filings stay in one place, updated in real time, with AI-powered summaries, expert notes, and full original PDFs ready for deep dives.
Deborah C. Jackson, a director of American Well Corporation (AMWL), reported a sale of 4,531 shares of Class A common stock on 08/19/2025 at a price of $7.1027 per share. The Form 4 states the sale was executed under a Rule 10b5-1 trading plan adopted May 20, 2025, and that the proceeds were used to pay the tax liability from restricted stock units that vested and settled on June 10, 2025. Following the reported transaction, the filing shows 48,194 shares held directly and 612 shares held indirectly by spouse. The Form 4 was signed by an attorney-in-fact on behalf of Ms. Jackson on 08/21/2025.
Form 144 notice from American Well Corporation (AMWL) shows a proposed sale of 13,593 common shares, with an aggregate market value of $98,549.25, to be sold approximately on 08/19/2025 on the NYSE through Morgan Stanley Smith Barney LLC. The shares were acquired as restricted stock units from the issuer on 06/18/2025 and the acquisition/payment date is listed as 06/18/2025. The filer reports no securities sold during the past three months. The form includes the standard representation that the selling person is not aware of any undisclosed material adverse information and references Rule 144 and Rule 10b5-1 considerations.
Roy Schoenberg, Executive Vice Chairman and Director of American Well Corporation (AMWL), was granted 25,000 restricted stock units (RSUs) on 08/13/2025. The RSUs vest in equal installments over three years from the grant date, with portions vesting on each of the first, second and third anniversaries. After giving effect to the reported grant and prior holdings (and adjusted for a 1-for-20 reverse stock split that took effect July 10, 2024), the reporting person beneficially owned 133,302 shares of Class A common stock. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Schoenberg on 08/14/2025.
Ido Schoenberg, Chairman and co-CEO of American Well Corp (AMWL), received a grant of 50,000 restricted stock units (RSUs) on 08/13/2025. The RSUs vest in equal installments over three years, with vesting on each of the first, second and third anniversaries of the grant date. After the reported transaction, the filing shows 114,250 shares of Class A common stock beneficially owned directly and an additional 136,891 shares of Class A common stock beneficially owned indirectly through his wife.
Selected financials (June 30, 2025)
Q2 revenue $70,898; three‑month net loss $19,531 (net loss attributable to American Well $19,696; EPS $(1.24)). Six months revenue $137,731; net loss $37,887 (attributable $38,400).
Balance sheet: cash and cash equivalents $219,072; total assets $388,656; total liabilities $94,083; total stockholders' equity $294,573; accumulated deficit $(2,004,326). Deferred revenue $43,259; transaction price allocated to remaining performance obligations $84,725 (71% expected in the 12 months ending June 30, 2026).
- Revenue mix: platform subscription $40,460; visits $22,752; other $7,686 (Q2).
- Divestiture: sale of APC business closed Jan 8, 2025; net proceeds reported $20,400 and a gain of $10,713 recognized in H1 2025.
FAQ
What is the current stock price of American Well (AMWL)?
What is the market cap of American Well (AMWL)?
